<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00383240</url>
  </required_header>
  <id_info>
    <org_study_id>P04334</org_study_id>
    <secondary_id>EUDRACT No.: 2006-001578-25;</secondary_id>
    <nct_id>NCT00383240</nct_id>
  </id_info>
  <brief_title>Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04334AM1)(COMPLETED)</brief_title>
  <official_title>A 26-Week Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate/Formoterol Fumarate Combination Formulation Compared With Mometasone Furoate and Formoterol Monotherapy in Subjects With Persistent Asthma Previously Treated With Medium-Dose Inhaled Glucocorticosteroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, multi-center, double-blind, double-dummy, placebo-controlled,
      parallel-group study, evaluating the efficacy of mometasone furoate (MF) /formoterol fumarate
      (F)[MF/F] metered dose inhaler (MDI) versus MF for 26 weeks. Prior to the 26-week
      double-blind Treatment Period, subjects will receive open-label MF MDI 200 mcg twice daily
      (BID) for 2 to 3 weeks during the Run-in Period. Efficacy will be measured by The Area Under
      the Curve From 0 to 12 Hours [AUC](0-12 hours) of the Change From Baseline to the Week 12
      Endpoint

      in Forced Expiratory Volume in One Second (FEV1) [Time Frame: Baseline to Week 12] and
      Time-to-First Severe Asthma Exacerbation across the 26-week treatment period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 12 in Forced Expiratory Volume (Liters) in 1 Second (FEV1) for MF/F Versus MF</measure>
    <time_frame>Baseline to Endpoint (12 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time-to-first Asthma Exacerbation Over the 26-week Treatment Period for the Comparison of MF/F Versus F</measure>
    <time_frame>26-week Treatment Period</time_frame>
    <description>This endpoint was to measure the time it took for 50% of subjects in a treatment arm to experience a severe asthma exacerbation (also see the posted Other Pre-specified Outcome: Number of Participants With at Least One Severe Asthma Exacerbation)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 26 in Asthma Quality of Life Questionnaire With Standardized Activities (AQLQ[S]) Total Score</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>AQLQ(S) consists of 32 questions each scaled from 1 (worst case) to 7 (best case). Standard deviations are pooled.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 26 in the Asthma Control Questionnaire (ACQ) Score</measure>
    <time_frame>Baseline to week 26</time_frame>
    <description>ACQ consists of seven questions each scaled from 0 (best case) to 6 (worst case).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Proportion of Nights Across the Treatment Period With Nocturnal Awakenings Due to Asthma Which Require Use of Short-acting Beta 2-agonist (SABA)</measure>
    <time_frame>Baseline to Endpoint</time_frame>
    <description>Baseline is the proportion of nights of last week (Days -7 to 1) prior to first dose with nocturnal awakenings. Scale is measured as 0 to 1 with 0=no awakenings to 1=awakenings every night. Standard deviation is pooled.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With at Least One Severe Asthma Exacerbation</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>A severe asthma exacerbation was defined as a clinically judged deterioration of asthma or a meaningful reduction in lung function based on any of the following criteria during the Treatment Period:
A decrease in FEV1 below the Treatment Period stability limit at any visit,
A decrease in AM or PM peak flow below the Treatment Period stability limits on any 2 consecutive days,
An occurrence of any clinical deterioration of asthma (ie, asthma attack) that resulted in emergency treatment, hospitalization due to asthma, or treatment with additional, excluded asthma medication.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">781</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>MF/F MDI 200/10 mcg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MF MDI 200 mcg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>F MDI 10 mcg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID</intervention_name>
    <description>MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 26 weeks</description>
    <arm_group_label>MF/F MDI 200/10 mcg BID</arm_group_label>
    <other_name>SCH 418131</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone furoate MDI (MF MDI) 200 mcg</intervention_name>
    <description>MF 200 mcg via metered dose inhaler twice daily for 26 weeks</description>
    <arm_group_label>MF MDI 200 mcg BID</arm_group_label>
    <other_name>SCH 32088</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>formoterol fumarate 10 mcg</intervention_name>
    <description>F via metered dose inhaler 10 mcg twice a day for 26 weeks</description>
    <arm_group_label>F MDI 10 mcg BID</arm_group_label>
    <other_name>Foradil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo metered dose inhaler twice a day for 26 weeks</description>
    <arm_group_label>Placebo BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Adult and adolescent subjects of either sex and any race, at least 12 years of age or
        older, with a diagnosis of asthma of at least 12 months' duration, will be eligible for
        enrollment. Subjects must meet all of the inclusion criteria and none of the exclusion
        criteria to receive treatment assignment.

        Key Inclusion Criteria Include

        - A subject must have been using a medium daily dose of inhaled glucocorticosteroid (ICS)
        (either alone or in combination with a long-acting beta agonist (LABA)) for at least 12
        weeks and must have been on a stable regimen (daily dose unchanged) for at least 2 weeks
        prior to Screening. Medium daily doses of ICS are defined as follows:

          -  &gt;500 to 1000 mcg beclomethasone chlorofluorocarbon (CFC)

          -  &gt;250 to 500 mcg beclomethasone hydrofluoroalkane (HFA)

          -  &gt;600 to 1000 mcg budesonide dry powder inhaler (DPI)

          -  &gt;1000 to 2000 mcg flunisolide

          -  &gt;250 to 500 mcg fluticasone

          -  400 mcg MF

          -  &gt;1000 to 2000 mcg triamcinolone acetonide

        Note: Dose delivery by method or modality other than those noted above must be equivalent.

          -  If, based upon the medical judgment of the investigator, there is no inherent harm in
             changing the subject's current asthma therapy, then the subject (and parent/guardian,
             if applicable) must be willing to discontinue his/her prescribed ICS or ICS/LABA
             combination at the Screening Visit, and be transferred to open-label treatment with MF
             MDI 200 mcg BID for 2 to 3 weeks prior to the Baseline/Randomization Visit.

          -  To document the diagnosis of asthma and assure the subject's responsiveness to
             bronchodilators before randomization one of the following methods can be used at the
             Screening Visit, Day -14, or thereafter, but prior to the Baseline Visit:

               1. The subject must demonstrate an increase in absolute FEV1 of at least 12% and at
                  least 200 mL within 15 minutes after administration of four inhalations of
                  albuterol/salbutamol (total dose of 360 to 400 mcg) or of nebulized SABA (2.5 mg)
                  if confirmed as standard office practice, OR

               2. The subject must demonstrate a peak expiratory flow (PEF) variability of more
                  than 20% expressed as a percentage of the highest and lowest morning
                  prebronchodilator PEF over at least 1 week, OR

               3. The subject must demonstrate a diurnal variation in PEF of more than 20% based on
                  the difference between the prebronchodilator morning value and the
                  postbronchodilator value from the evening before, expressed as a percentage of
                  the mean daily PEF value.

          -  At the Screening Visit, the subject's FEV1 must be ≥60% and ≤90% predicted.

          -  At the Baseline Visit, the subject's FEV1 must be ≥60% and ≤85% predicted when all
             restricted medications have been withheld for the appropriate intervals.

          -  Clinical laboratory tests (complete blood counts [CBC], blood chemistries, and
             urinalysis) conducted at the Screening Visit must be within normal limits or
             clinically acceptable to the investigator/sponsor. An electrocardiogram (ECG) using a
             centralized trans-telephonic technology at the Screening Visit must be clinically
             acceptable to the investigator. A chest x-ray performed at the Screening Visit, or
             within 12 months prior to the Screening Visit, must be clinically acceptable to the
             investigator.

          -  A female subject of childbearing potential must have been using a medically
             acceptable, adequate form of birth control. This includes: 1) hormonal contraceptives
             as prescribed by a physician (oral combined, hormonal implant); 2) medically
             prescribed intra-uterine device (IUD); 3) condom in combination with a spermicide
             (double barrier method); 4) monogamous relationship with a male partner who has had a
             vasectomy. The subject must have started this birth control method at least 3 months
             prior to Screening (with the exception of condom in combination with spermicide), and
             must agree to continue its use for the duration of the study. A female subject of
             childbearing potential who is not currently sexually active must agree and consent to
             using a medically acceptable birth control method should she become sexually active
             during the course of this study. Women who have been surgically sterilized or are at
             least 1 year postmenopausal are not considered to be of childbearing potential. A
             female subject of childbearing potential must have a negative serum pregnancy test at
             Screening in order to be considered eligible for enrollment.

        Key Exclusion Criteria Include

          -  A subject who demonstrates a change (increase or decrease) in absolute FEV1 of &gt;20% at
             any time from the Screening Visit up to and including the Baseline Visit.

          -  A subject who requires the use of greater than eight inhalations per day of SABA MDI,
             or two or more nebulized treatments per day of 2.5 mg SABA, on any 2 consecutive days
             from the Screening Visit up to and including the Baseline Visit.

          -  A subject who experiences a decrease in AM or PM PEF below the Screening Period
             stability limit on any 2 consecutive days prior to Randomization.

          -  A subject who experiences an occurrence of any clinical deterioration of asthma that
             results in emergency treatment, hospitalization due to asthma, or treatment with
             additional, excluded asthma medication (other than SABA) as judged by the clinical
             investigator at any time from the Screening Visit up to and including the Baseline
             Visit.

          -  A subject who is a smoker or ex-smoker and has smoked within the previous year or has
             had a cumulative smoking history &gt;10 pack-years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Costa Rica</country>
    <country>Croatia</country>
    <country>Denmark</country>
    <country>Ecuador</country>
    <country>Estonia</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2006</study_first_submitted>
  <study_first_submitted_qc>September 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2006</study_first_posted>
  <results_first_submitted>June 30, 2010</results_first_submitted>
  <results_first_submitted_qc>February 10, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 7, 2011</results_first_posted>
  <disposition_first_submitted>October 22, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>October 22, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 26, 2009</disposition_first_posted>
  <last_update_submitted>March 13, 2017</last_update_submitted>
  <last_update_submitted_qc>March 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MF/F MDI 200/10 mcg BID</title>
          <description>mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 200/10 mcg twice daily (BID) for 26 weeks</description>
        </group>
        <group group_id="P2">
          <title>MF MDI 200 mcg BID</title>
          <description>Mometasone furoate (MF) MDI 200 mcg BID for 26 weeks</description>
        </group>
        <group group_id="P3">
          <title>F MDI 10 mcg BID</title>
          <description>Formoterol fumarate (F) MDI 10 mcg BID for 26 weeks</description>
        </group>
        <group group_id="P4">
          <title>Placebo BID</title>
          <description>Placebo MDI BID for 26 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="191"/>
                <participants group_id="P2" count="192"/>
                <participants group_id="P3" count="202"/>
                <participants group_id="P4" count="196"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="156"/>
                <participants group_id="P2" count="159"/>
                <participants group_id="P3" count="117"/>
                <participants group_id="P4" count="119"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="85"/>
                <participants group_id="P4" count="77"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment Failure</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="46"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by subject, reasons unrelated</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by subjects, reasons related</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet protocol eligibility</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MF/F MDI 200/10 mcg BID</title>
          <description>mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 200/10 mcg twice daily (BID) for 26 weeks</description>
        </group>
        <group group_id="B2">
          <title>MF MDI 200 mcg BID</title>
          <description>Mometasone furoate (MF) MDI 200 mcg BID for 26 weeks</description>
        </group>
        <group group_id="B3">
          <title>F MDI 10 mcg BID</title>
          <description>Formoterol fumarate (F) MDI 10 mcg BID for 26 weeks</description>
        </group>
        <group group_id="B4">
          <title>Placebo BID</title>
          <description>Placebo MDI BID for 26 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="191"/>
            <count group_id="B2" value="192"/>
            <count group_id="B3" value="202"/>
            <count group_id="B4" value="196"/>
            <count group_id="B5" value="781"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="173"/>
                    <measurement group_id="B3" value="174"/>
                    <measurement group_id="B4" value="169"/>
                    <measurement group_id="B5" value="677"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.9" spread="16.3"/>
                    <measurement group_id="B2" value="42.8" spread="14.9"/>
                    <measurement group_id="B3" value="41.9" spread="15.3"/>
                    <measurement group_id="B4" value="41.9" spread="15.3"/>
                    <measurement group_id="B5" value="42.4" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="129"/>
                    <measurement group_id="B4" value="122"/>
                    <measurement group_id="B5" value="460"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="74"/>
                    <measurement group_id="B5" value="321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 12 in Forced Expiratory Volume (Liters) in 1 Second (FEV1) for MF/F Versus MF</title>
        <time_frame>Baseline to Endpoint (12 weeks)</time_frame>
        <population>Intent to Treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 200/10 mcg BID</title>
            <description>mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 200/10 mcg twice daily (BID) for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>MF MDI 200 mcg BID</title>
            <description>Mometasone furoate (MF) MDI 200 mcg BID for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>F MDI 10 mcg BID</title>
            <description>Formoterol fumarate (F) MDI 10 mcg BID for 26 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>Placebo MDI BID for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 12 in Forced Expiratory Volume (Liters) in 1 Second (FEV1) for MF/F Versus MF</title>
          <population>Intent to Treat (ITT) population</population>
          <units>liters x hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="190"/>
                <count group_id="O3" value="202"/>
                <count group_id="O4" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=188/189/198/192, respectively)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.20" spread="2.96"/>
                    <measurement group_id="O2" value="1.29" spread="2.96"/>
                    <measurement group_id="O3" value="2.73" spread="2.96"/>
                    <measurement group_id="O4" value="1.42" spread="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (Change from Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.19" spread="3.98"/>
                    <measurement group_id="O2" value="1.31" spread="3.98"/>
                    <measurement group_id="O3" value="1.60" spread="3.98"/>
                    <measurement group_id="O4" value="0.51" spread="3.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>P-Value for Endpoint</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>P-Value for Endpoint</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>P-Value for Endpoint</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.491</p_value>
            <p_value_desc>P-Value for Endpoint</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.055</p_value>
            <p_value_desc>P-Value for Endpoint</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>P-Value for Endpoint</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 26 in Asthma Quality of Life Questionnaire With Standardized Activities (AQLQ[S]) Total Score</title>
        <description>AQLQ(S) consists of 32 questions each scaled from 1 (worst case) to 7 (best case). Standard deviations are pooled.</description>
        <time_frame>Baseline to Week 26</time_frame>
        <population>ITT population with non-missing post-baseline AQLQ result</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 200/10 mcg BID</title>
            <description>mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 200/10 mcg twice daily (BID) for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>MF MDI 200 mcg BID</title>
            <description>Mometasone furoate (MF) MDI 200 mcg BID for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>F MDI 10 mcg BID</title>
            <description>Formoterol fumarate (F) MDI 10 mcg BID for 26 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>Placebo MDI BID for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 26 in Asthma Quality of Life Questionnaire With Standardized Activities (AQLQ[S]) Total Score</title>
          <description>AQLQ(S) consists of 32 questions each scaled from 1 (worst case) to 7 (best case). Standard deviations are pooled.</description>
          <population>ITT population with non-missing post-baseline AQLQ result</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="189"/>
                <count group_id="O3" value="187"/>
                <count group_id="O4" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=183/189/187/189, respectively)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.38" spread="1.10"/>
                    <measurement group_id="O2" value="5.40" spread="1.13"/>
                    <measurement group_id="O3" value="5.51" spread="1.11"/>
                    <measurement group_id="O4" value="5.56" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Endpoint (26 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="0.85"/>
                    <measurement group_id="O2" value="0.37" spread="0.85"/>
                    <measurement group_id="O3" value="0.05" spread="0.85"/>
                    <measurement group_id="O4" value="-0.01" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.174</p_value>
            <p_value_desc>P-Value for Endpoint</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>P-Value for Endpoint</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>P-Value for Endpoint</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>P-Value for Endpoint</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>P-Value for Endpoint</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.521</p_value>
            <p_value_desc>P-Value for Endpoint</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time-to-first Asthma Exacerbation Over the 26-week Treatment Period for the Comparison of MF/F Versus F</title>
        <description>This endpoint was to measure the time it took for 50% of subjects in a treatment arm to experience a severe asthma exacerbation (also see the posted Other Pre-specified Outcome: Number of Participants With at Least One Severe Asthma Exacerbation)</description>
        <time_frame>26-week Treatment Period</time_frame>
        <population>All Randomized Subjects</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 200/10 mcg BID</title>
            <description>mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 200/10 mcg twice daily (BID) for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>MF MDI 200 mcg BID</title>
            <description>Mometasone furoate (MF) MDI 200 mcg BID for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>F MDI 10 mcg BID</title>
            <description>Formoterol fumarate (F) MDI 10 mcg BID for 26 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>Placebo MDI BID for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Time-to-first Asthma Exacerbation Over the 26-week Treatment Period for the Comparison of MF/F Versus F</title>
          <description>This endpoint was to measure the time it took for 50% of subjects in a treatment arm to experience a severe asthma exacerbation (also see the posted Other Pre-specified Outcome: Number of Participants With at Least One Severe Asthma Exacerbation)</description>
          <population>All Randomized Subjects</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="192"/>
                <count group_id="O3" value="202"/>
                <count group_id="O4" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Since less than 50% of the subjects in the MF/F and MF treatment groups experienced an asthma exacerbation by the end of the 26 week treatment period, median time-to-first asthma exacerbation can not be determined but is at least 26 weeks.</measurement>
                    <measurement group_id="O2" value="NA">Since less than 50% of the subjects in the MF/F and MF treatment groups experienced an asthma exacerbation by the end of the 26 week treatment period, median time-to-first asthma exacerbation can not be determined but is at least 26 weeks.</measurement>
                    <measurement group_id="O3" value="92" lower_limit="24">In the F treatment group a subject experienced an asthma exacerbation on day 193 since the event was observed on the final visit performed 10 days beyond the scheduled 26-week treatment period schedule. Therefore the InterQuartile Range is 24 to 193.</measurement>
                    <measurement group_id="O4" value="131" lower_limit="25">Since less than 75% of the subjects in the placebo group experienced an asthma exacerbation by the end of the 26 week treatment period, 3rd quartile time-to-first asthma exacerbation can not be determined but is at least 26 weeks.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 26 in the Asthma Control Questionnaire (ACQ) Score</title>
        <description>ACQ consists of seven questions each scaled from 0 (best case) to 6 (worst case).</description>
        <time_frame>Baseline to week 26</time_frame>
        <population>ITT population with non-missing post-baseline ACQ result</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 200/10 mcg BID</title>
            <description>mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 200/10 mcg twice daily (BID) for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>MF MDI 200 mcg BID</title>
            <description>Mometasone furoate (MF) MDI 200 mcg BID for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>F MDI 10 mcg BID</title>
            <description>Formoterol fumarate (F) MDI 10 mcg BID for 26 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>Placebo MDI BID for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 26 in the Asthma Control Questionnaire (ACQ) Score</title>
          <description>ACQ consists of seven questions each scaled from 0 (best case) to 6 (worst case).</description>
          <population>ITT population with non-missing post-baseline ACQ result</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="186"/>
                <count group_id="O3" value="184"/>
                <count group_id="O4" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=179/186/184/187, respectively)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="0.75"/>
                    <measurement group_id="O2" value="1.46" spread="0.77"/>
                    <measurement group_id="O3" value="1.43" spread="0.79"/>
                    <measurement group_id="O4" value="1.41" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Endpoint (week 26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.74"/>
                    <measurement group_id="O2" value="-0.23" spread="0.74"/>
                    <measurement group_id="O3" value="0.11" spread="0.74"/>
                    <measurement group_id="O4" value="0.14" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.026</p_value>
            <p_value_desc>P-Value for Endpoint</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>P-Value for Endpoint</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>P-Value for Endpoint</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>P-Value for Endpoint</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>P-Value for Endpoint</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.738</p_value>
            <p_value_desc>P-Value for Endpoint</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Proportion of Nights Across the Treatment Period With Nocturnal Awakenings Due to Asthma Which Require Use of Short-acting Beta 2-agonist (SABA)</title>
        <description>Baseline is the proportion of nights of last week (Days -7 to 1) prior to first dose with nocturnal awakenings. Scale is measured as 0 to 1 with 0=no awakenings to 1=awakenings every night. Standard deviation is pooled.</description>
        <time_frame>Baseline to Endpoint</time_frame>
        <population>ITT population from the entire 26-week treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 200/10 mcg BID</title>
            <description>mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 200/10 mcg twice daily (BID) for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>MF MDI 200 mcg BID</title>
            <description>Mometasone furoate (MF) MDI 200 mcg BID for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>F MDI 10 mcg BID</title>
            <description>Formoterol fumarate (F) MDI 10 mcg BID for 26 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>Placebo MDI BID for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Proportion of Nights Across the Treatment Period With Nocturnal Awakenings Due to Asthma Which Require Use of Short-acting Beta 2-agonist (SABA)</title>
          <description>Baseline is the proportion of nights of last week (Days -7 to 1) prior to first dose with nocturnal awakenings. Scale is measured as 0 to 1 with 0=no awakenings to 1=awakenings every night. Standard deviation is pooled.</description>
          <population>ITT population from the entire 26-week treatment period</population>
          <units>Ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="191"/>
                <count group_id="O3" value="199"/>
                <count group_id="O4" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=186/191/199/194, respectively)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.31"/>
                    <measurement group_id="O2" value="0.16" spread="0.27"/>
                    <measurement group_id="O3" value="0.16" spread="0.27"/>
                    <measurement group_id="O4" value="0.15" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.17"/>
                    <measurement group_id="O2" value="-0.05" spread="0.17"/>
                    <measurement group_id="O3" value="0.01" spread="0.17"/>
                    <measurement group_id="O4" value="0.00" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.063</p_value>
            <p_value_desc>P-Value for endpoint</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>P-Value for Endpoint</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>P-Value for Endpoint</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>P-Value for Endpoint</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>P-Value for Endpoint</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.601</p_value>
            <p_value_desc>P-Value for Endpoint</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With at Least One Severe Asthma Exacerbation</title>
        <description>A severe asthma exacerbation was defined as a clinically judged deterioration of asthma or a meaningful reduction in lung function based on any of the following criteria during the Treatment Period:
A decrease in FEV1 below the Treatment Period stability limit at any visit,
A decrease in AM or PM peak flow below the Treatment Period stability limits on any 2 consecutive days,
An occurrence of any clinical deterioration of asthma (ie, asthma attack) that resulted in emergency treatment, hospitalization due to asthma, or treatment with additional, excluded asthma medication.</description>
        <time_frame>Baseline to Week 26</time_frame>
        <population>All Randomized Subjects</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 200/10 mcg BID</title>
            <description>mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 200/10 mcg twice daily (BID) for 26 weeks</description>
          </group>
          <group group_id="O2">
            <title>MF MDI 200 mcg BID</title>
            <description>Mometasone furoate (MF) MDI 200 mcg BID for 26 weeks</description>
          </group>
          <group group_id="O3">
            <title>F MDI 10 mcg BID</title>
            <description>Formoterol fumarate (F) MDI 10 mcg BID for 26 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>Placebo MDI BID for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least One Severe Asthma Exacerbation</title>
          <description>A severe asthma exacerbation was defined as a clinically judged deterioration of asthma or a meaningful reduction in lung function based on any of the following criteria during the Treatment Period:
A decrease in FEV1 below the Treatment Period stability limit at any visit,
A decrease in AM or PM peak flow below the Treatment Period stability limits on any 2 consecutive days,
An occurrence of any clinical deterioration of asthma (ie, asthma attack) that resulted in emergency treatment, hospitalization due to asthma, or treatment with additional, excluded asthma medication.</description>
          <population>All Randomized Subjects</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="192"/>
                <count group_id="O3" value="202"/>
                <count group_id="O4" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="109"/>
                    <measurement group_id="O4" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>OL MF MDI 200 MCG BID</title>
          <description>Participants received 2 to 3 weeks (approximately) of open-label (OL), run-in medication with MF MDI 200 mcg BID prior to the 26-week double-blind treatment period.</description>
        </group>
        <group group_id="E2">
          <title>MF/F MDI 200/10 MCG BID</title>
        </group>
        <group group_id="E3">
          <title>MF MDI 200 MCG BID</title>
        </group>
        <group group_id="E4">
          <title>F MDI 10 MCG BID</title>
        </group>
        <group group_id="E5">
          <title>PLACEBO</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="984"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>DENGUE FEVER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>JOINT INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>UTERINE LEIOMYOSARCOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>ENDOMETRIOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>UTERINE HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="984"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>VAGINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATITIS ATOPIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>SPINAL DECOMPRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="984"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="984"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="191"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="192"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="202"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="984"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="191"/>
                <counts group_id="E3" events="22" subjects_affected="15" subjects_at_risk="192"/>
                <counts group_id="E4" events="14" subjects_affected="13" subjects_at_risk="202"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="984"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="191"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="192"/>
                <counts group_id="E4" events="16" subjects_affected="12" subjects_at_risk="202"/>
                <counts group_id="E5" events="17" subjects_affected="17" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="984"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="191"/>
                <counts group_id="E3" events="17" subjects_affected="10" subjects_at_risk="192"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="202"/>
                <counts group_id="E5" events="10" subjects_affected="7" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

